Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter Phase 1-2 Study to Investigate the Effectiveness, Safety and Immunogenicity of a Monotherapy With Intradermal IMA910 Plus GM-CSF Following Pre-treatment With Low-dose Cyclophosphamide in Advanced Colorectal Carcinoma Patients Who Have Successfully Completed a 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy.

NCT00785122 is registered in ClinicalTrials.gov with Immatics Biotechnologies GmbH as lead sponsor.

NCT NCT00785122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00785122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter Phase 1-2 Study to Investigate the Effectiveness, Safety and Immunogenicity of a Monotherapy With Intradermal IMA910 Plus GM-CSF Following Pre-treatment With Low-dose Cyclophosphamide in Advanced Colorectal Carcinoma Patients Who Have Successfully Completed a 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy.
Lead sponsor
Immatics Biotechnologies GmbH
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2008
Completion date
May 31, 2013
Enrollment
92 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma